Puncher for cell line Development (Q3989339): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Fix Beneficiary from Netherlands)
(‎Changed an Item: Fix Beneficiary from Netherlands)
Property / beneficiary name (string)
 
Universiteit Twente
Property / beneficiary name (string): Universiteit Twente / rank
 
Normal rank
Property / beneficiary
 
Property / beneficiary: Q3985142 / rank
 
Normal rank

Revision as of 09:34, 16 December 2021

Project Q3989339 in Netherlands
Language Label Description Also known as
English
Puncher for cell line Development
Project Q3989339 in Netherlands

    Statements

    0 references
    0 references
    283,786.04 Euro
    0 references
    1,542,992.97 Euro
    0 references
    18.392 percent
    0 references
    11 May 2020
    0 references
    30 June 2023
    0 references
    JB Ventures
    0 references
    Kane Tronics
    0 references
    Stevens Ide partners
    0 references
    Universiteit Twente
    0 references
    0 references
    0 references
    0 references
    0 references

    52°21'31.14"N, 6°30'15.73"E
    0 references
    7442CL
    0 references
    In dit project zal een Puncher platform demonstrator worden gerealiseerd en gevalideerd om hiermee antilichaam producerende monoclonale cellijnen sneller en kosten effectiever te ontwikkelen. Antilichamen worden gebruikt bij de behandeling van kan... (Dutch)
    0 references
    In this project, a Puncher platform demonstrator will be realised and validated to develop antibody-producing monoclonal cell lines more quickly and cost effectively. Antibodies are used in the treatment of... (English)
    15 December 2021
    0 references
    Dans le cadre de ce projet, un démonstrateur de plateforme Puncher sera réalisé et validé afin de développer des lignées cellulaires monoclonales produisant des anticorps plus rapidement et plus efficacement. Les anticorps sont utilisés dans le traitement de... (French)
    15 December 2021
    0 references
    In diesem Projekt wird ein Puncher-Plattform-Demonstrator realisiert und validiert, um antikörperproduzierende monoklonale Zelllinien schneller und kostengünstiger zu entwickeln. Antikörper werden bei der Behandlung von... (German)
    15 December 2021
    0 references

    Identifiers

    OP-2014-2023-Oost-PROJ-00971
    0 references